Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Provided herein are compounds of formula I, compositions comprising the compounds and method of treating various diseases with the compounds and compositions.

The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction.

The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

A method for synthesizing a ketoxime is provided. In a system of an aqueous carbonate solution, a reaction is performed on a ketone, ammonia and hydrogen peroxide by using a titanium-silicon molecular sieve as a catalyst to obtain the ketoxime. Moreover, a reaction progress is judged and an optimal reaction ratio is determined by a real-time monitoring of a pH value in a reaction system during the reaction. In the present invention, by monitoring the pH value in the reaction system, the progress of the reaction is judged, thereby determining the optimal reaction ratio. The pH of the system is further adjusted by an aqueous carbonate solution to increase the reaction velocity and conversion rate of the ammonia.

A method for synthesizing a ketoxime is provided. In a system of an aqueous carbonate solution, a reaction is performed on a ketone, ammonia and hydrogen peroxide by using a titanium-silicon molecular sieve as a catalyst to obtain the ketoxime. Moreover, a reaction progress is judged and an optimal reaction ratio is determined by a real-time monitoring of a pH value in a reaction system during the reaction. In the present invention, by monitoring the pH value in the reaction system, the progress of the reaction is judged, thereby determining the optimal reaction ratio. The pH of the system is further adjusted by an aqueous carbonate solution to increase the reaction velocity and conversion rate of the ammonia.

A compound represented by a formula [1D] as shown below (wherein R.sup.1A, R.sup.1B, R.sup.2A, R.sup.2B, R.sup.3A and R.sup.3B represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside. ##STR00001##